Interview with Kim Yongwook, Director of Gangnam Severance Hospital ②


AI Medical Devices and Digital Therapeutics: "Urgent Need for Reimbursement Systems"

"Regulations on Medical Data and Research Personnel Also Hinder Commercialization"

"Both development and regulatory approval have been achieved, but reimbursement has not been determined. In this situation, hospitals find it difficult to prescribe the technology, and the companies that developed it cannot generate sales, eventually collapsing."


Of the 27 civilian members of the National Bio-Innovation Committee (hereafter referred to as the Innovation Committee), most are medical school professors or business leaders. Kim Yongwook, Director of Gangnam Severance Hospital, is the only current hospital director among them. When asked why a hospital administrator—neither a researcher nor a businessperson—is needed in this role, Director Kim first brought up the concept of the "death valley." This refers to the phenomenon where technologies are abandoned due to a lack of funding and institutional support in the period between research achievements passing clinical trials and making it to market. Director Kim likened the hospital director to a "problem solver" in this stage. He emphasized that hospitals are the entities best positioned to comprehensively assess the costs, risks, and benefits that arise when new technologies are introduced into healthcare settings.


Kim Yongwook, Director of Gangnam Severance Hospital, is responding in an interview with this publication. Photo by Dongju Yoon

Kim Yongwook, Director of Gangnam Severance Hospital, is responding in an interview with this publication. Photo by Dongju Yoon

View original image

The companies that experience this "death valley" most acutely are those developing medical artificial intelligence (AI) solutions and digital therapeutics (DTx). Unlike new drug developers, who compete globally by exporting technology, these companies generate sales by supplying products to domestic healthcare institutions and relying on health insurance reimbursement. For them, the reimbursement system is a lifeline. The critical juncture that determines whether they cross the death valley is, in fact, reimbursement. Director Kim stressed, "Reimbursement is the most important issue I can address as a hospital director." No matter how advanced AI or digital technology is, it is useless if it is not adopted in clinical settings.


Under the current reimbursement system, these technologies are either bundled with existing procedure fees or not properly recognized, resulting in losses for hospitals that adopt them or forcing costs onto patients. Director Kim stated, "If improvements to the reimbursement system are delayed, domestic companies will fail to cross the death valley due to funding shortages even before they can truly grow," adding, "A suitable reimbursement system must be established quickly so that companies can maintain a stable financial structure and expand into the global market."


The challenging financial structure of hospitals also impedes the adoption of new technologies. University hospitals have an operating profit margin of less than 1%. Even if they generate 10 billion won in revenue, less than 100 million won remains as net profit. With clinical revenue barely sufficient for reinvestment and research, it is difficult to take on technologies that lack reimbursement. The situation is even more urgent for companies. As investment funds that should support the bio-healthcare sector are increasingly redirected to semiconductors, the momentum to sustain these technologies is drying up. Director Kim remarked, "Even when good technologies are developed, many companies end up closing or going out of business," and added, "For hospitals to quickly adopt these technologies and use them in patient care is the very path to growing the industry."

Data and Talent Also Hold Back Progress..."A System Is Needed to Bridge Research and Industry"

Alongside reimbursement, Director Kim identified medical data as another bottleneck. Data is the raw material for AI drug development and precision medicine, but ambiguity over responsibility for its use hinders industrialization. In December last year, the Personal Information Protection Act was strengthened, raising the upper limit of fines for data breaches from 3% to 10% of sales. Director Kim noted, "If a company gets caught, it could go bankrupt, so everyone becomes cautious about using data." Multiple internal reviews are required to determine whether data has been properly anonymized and who bears post-usage responsibility. According to him, it is up to institutional operators to design the structure of responsibility between hospitals holding the data and companies utilizing it.


The issue of research personnel also acts as a roadblock to industrialization. Director Kim emphasized that for the bio industry to grow, physician-scientists (MD-PhDs) who can bridge clinical practice and research are essential. According to him, Yonsei University Health System has trained the largest number of physician-scientists in Korea, with about 70 individuals. However, once in the field, they cannot focus solely on research; they must also engage in patient care. Director Kim pointed out, "It's a structure where they see patients during the day and do research at night—a classic example of working by day and studying by night. There is no reward system that allows them to devote themselves to research."


[Bio Story]②"Even After Development and Approval, the Reimbursement Barrier Remains... Companies Collapse" View original image

Initiatives at the hospital level have already begun. Since last year, Yonsei University Health System has revised its faculty evaluation metrics. Whereas evaluations were previously centered on publications, they have begun factoring in achievements in patents and technology transfer. This has shifted incentives to encourage linking research outcomes to industry. However, as the new system has been in place for less than a year, its limitations are clear. Government evaluations of tertiary hospitals still focus on the number and severity of patients treated. Even if research capabilities are strengthened, they are not reflected in evaluation metrics, and hospital operations remain tethered to clinical revenue. Director Kim commented, "Although the government claims to be fostering research-centered hospitals, in reality, field evaluation criteria are still heavily focused on clinical care."



Ultimately, Director Kim's main message within the Innovation Committee is the need to revise the system that connects research with industry. This encompasses financial support for hospitals adopting innovative medical technologies to offset losses, a reward system that enables physician-scientists to dedicate themselves to research, and the establishment of legal guidelines on liability for the use of medical data. All these measures call for a robust framework of compensation and responsibility to ensure that technologies can take root in the market. He concluded, "Only when products are properly valued can new ones be developed," stressing that discussions about adequate compensation can no longer be postponed.

[Bio Story]②"Even After Development and Approval, the Reimbursement Barrier Remains... Companies Collapse" View original image


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing